Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

ere adjudicated by a blinded, independent central adjudication committee. The study was not powered to show a dose response with PRT054021 or efficacy of PRT054021 versus enoxaparin.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a twenty hour pharmacodynamic half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function. PRT054021 is expected to enter Phase III clinical development in the first half of 2008.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
(Date:5/21/2015)... 21, 2015 Research and ... of the "Market Assessment of Respiratory Diagnostics ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This ... imaging diagnostics market in the United ... . The service provides detailed analysis of the ...
(Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4United States and Europe Respiratory Diagnostics Market Assessment 2015 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... Texas, Jan. 3, 2012  MacuCLEAR, Inc., a specialty clinical ... novel solutions for vascular disorders of the eye, ... in funds from current investors.  The funds will ... human efficacy trial for its lead product, MC-1101.  ...
... Jan. 3, 2012 Actavis Group, an international ... begun shipping Clobetasol Propionate Shampoo and Clobetasol Propionate ... Shampoo and Clobex ® Topical Lotion.  Due ... Actavis a 180-day marketing exclusivity. Combined ...
Cached Medicine Technology:MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership 2Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion 2
(Date:5/24/2015)... (PRWEB) May 24, 2015 Medicx ... Millennial Media strategy executive Jay Krihak as its ... looks to ramp up its expertise and leadership ... the Pharmaceutical and Health sectors. , Krihak is ... executive. Most recently, Krihak led sales planning teams ...
(Date:5/23/2015)... Dr. David Benvenuti, an experienced plastic surgeon who practices ... article to his website that takes an in-depth look ... in the fascinating blog, he has recently had several young ... as “gauging,” the technique involves placing larger and larger gauge ... eventually stretch the holes out to incredible sizes. As the ...
(Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Pioneer Millworks, ... at the forefront of designing with reclaimed wood, introducing ... in Los Angeles, California. Their newest offerings, Vat 35, ... much-anticipated surface and color to America's largest design event. ... exhibit at each show, anxious to see and feel ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
Breaking Medicine News(10 mins):Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Ascenta Skin President Announces Plans to Grow Brand 2
... Men,s Health Network & Former Governor Gary Locke ... Oct. 4 Men,s Health Network,American Cancer Society, ... key thought leaders, community organizations, and,policy makers to ... Washington,State. Among presenters will be Former Washington Governor ...
... in Disguise, CHICAGO, Oct. 4 Let,s face ... But it,s easy for moms to make Halloween a ... recommend a,treat that won,t haunt anyone,s health: chocolate milk. ... This Official Drink of,Halloween has the chocolaty taste that ...
... Bioponic Phytoceuticals,Inc. (Pink Sheets: BPYT) ("Bioponic"), an ... the Complementary Alternative,Medicine (CAM) and nutraceutical markets, announced ... division of National Financial,Communications Corporation, as its investor ... billion in 2005, and approximately 62% of U.S.,adults ...
... This Week at Major Medical Meeting Reinforce Need for ... Broader Spectrum Pneumococcal Vaccines -, ... (NYSE: WYE ), comments on studies to be,presented this ... of America (IDSA) concerning PREVNAR(R) (Pneumococcal 7-valent,Conjugate Vaccine [Diphtheria CRM197 ...
... BOULDER, Colo., Oct. 4 On October 3, 2007,Encision ... received a letter,from the American Stock Exchange ("AMEX") stating ... with AMEX,s continued listing,standards, and granted the Company an ... continued listing standards. As previously disclosed, on July ...
... Oct. 4 More than 35,million children between the ... in,costume this Halloween. Although hours of planning and preparation ... to consider,the importance of security. "Today, most parents check ... sealed wrapper and safe to eat," says Steve,Jones, executive ...
Cached Medicine News:Health News:Washington Comes Together to Promote Smoking Cessation 2Health News:Chocolate Milk: 'The Official Drink of Halloween' 2Health News:Chocolate Milk: 'The Official Drink of Halloween' 3Health News:Chocolate Milk: 'The Official Drink of Halloween' 4Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 2Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 4Health News:American Stock Exchange Accepts Encision's Plan to Regain Compliance 2Health News:Safety Tips for a Fun and Spooky Halloween 2
... P with Tobramycin is the ... formula, with the addition of ... the original formula, surgeons can ... of Simplex™ P Bone Cement, ...
... Sir John Charnley and CMW, Inc. ... develop bone cements exclusively for orthopaedic ... 40 years of performance and excellence ... offers one of the first proven ...
... 35 years, Palacos Bone Cement ... the gold standard in cemented ... introduction of,the Optivac system in ... provided thousands of physicians the ...
... device for ocular precision tonometry. ,The PASCAL ... digital, contact tonometer for ophthalmological applications. The ... intra-ocular pressure (IOP) and of ocular pulse ... a few seconds. It measures pulsatile IOP ...
Medicine Products: